logo
Share SHARE
FONT-SIZE Plus   Neg

GlaxoSmithKline Announces Regulatory Submission To FDA For Albiglutide

GlaxoSmithKline plc (GSK, GSK.L) announced a regulatory submission to the US FDA for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes. GlaxoSmithKline intends to submit a regulatory application in the European Union in early 2013.

Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. Albiglutide is not yet approved as a treatment for type 2 diabetes or any other indication anywhere in the world.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Theme park chain Six Flags Entertainment Corp. (SIX) announced that it is in "discussions" with the Kingdom of Saudi Arabia to open multiple amusement parks in the conservative Muslim kingdom. Texas-based Six Flags Entertainment says it "has initiated discussions with the government of Saudi Arabia... Uber has developed new software that will track and inform drivers of the ride-hailing app about things like sudden acceleration, harsh braking or whether they are holding their phones while driving. The software is part of an updated version of Uber's app for drivers. One third of its PlayStation Plus users pay for games, Sony revealed on Wednesday.
comments powered by Disqus
Follow RTT